Published: 17 May 2021
Author(s): Evangelos Terpos, Dimitris Stellas, Margherita Rosati, Theodoros N. Sergentanis, Xintao Hu, Marianna Politou, Vassiliki Pappa, Ioannis Ntanasis-Stathopoulos, Sevasti Karaliota, Jenifer Bear, Duncan Donohue, Maria Pagoni, Elisavet Grouzi, Eleni Korompoki, George N. Pavlakis, Barbara K. Felber, Meletios A. Dimopoulos
Issue: July 2021
Section: Research paper

The duration of antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an area of extensive research in light of the new approvals of vaccines against SARS-CoV-2 and the use of convalescent plasma for patients with coronavirus disease 2019 (COVID-19) [1-4]. Production of anti-SARS-CoV-2 antibodies is observed in almost all symptomatic patients with COVID-19 and the elevated titers correlate with the severity of the symptoms [5-9]. Several observational studies have reported that asymptomatic individuals have also developed anti-SARS-CoV-2 antibodies [10-13].

Newsletters

Stay informed on our latest news!